{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:11:01Z","timestamp":1768345861847,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>A case of infusion-related angioedema associated with the use of an infliximab biosimilar (infliximab-abda) is reported in order to bring awareness that this adverse effect is still highly possible in biosimilars, similar to the reference infliximab biologic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 37-year-old white male with a past medical history significant for ileocolonic fistulizing Crohn\u2019s disease, depression, and gastroesophageal reflux disease (GERD) presented to an emergency department with shortness of breath, urticaria, and tongue swelling that had developed shortly after initiation of an infusion of infliximab-abda. The patient had no documented allergies at the time of presentation. The patient was taking oral budesonide 9 mg daily and oral azathioprine 50 mg daily for treatment of Crohn\u2019s disease. Other medications included oral omeprazole 40 mg every morning for GERD and oral sertraline 100 mg daily for depression. The patient\u2019s tongue swelling worsened, and he was intubated for airway protection. The patient received supportive care treatment for angioedema with intravenous (IV) dexamethasone 8 mg every 8 hours, IV diphenhydramine 50 mg every 8 hours, and IV famotidine 20 mg every 12 hours. He was extubated approximately 43 hours later and observed overnight in a medical intensive care unit. He was transferred to a general medicine unit the next day for further care. The total hospital length of stay was 4 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A 37-year-old man developed infusion-related angioedema with use of infliximab-abda. Discontinuation of the biosimilar product along with supportive care brought about resolution of angioedema. There are no prior published reports of infusion-related angioedema reactions secondary to infliximab-abda use.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa321","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T20:19:51Z","timestamp":1602188391000},"page":"108-112","source":"Crossref","is-referenced-by-count":4,"title":["Infusion-related angioedema associated with infliximab-abda: Case report"],"prefix":"10.1093","volume":"78","author":[{"given":"Kyle","family":"Herndon","sequence":"first","affiliation":[{"name":"Memphis Veterans Affairs Medical Center, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Dewitt","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Tennessee, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Gillion","sequence":"additional","affiliation":[{"name":"Memphis Veterans Affairs Medical Center, Memphis, TN, and College of Pharmacy, University of Tennessee, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debendra","family":"Pattanaik","sequence":"additional","affiliation":[{"name":"Memphis Veterans Affairs Medical Center, Memphis, TN, and College of Medicine, University of Tennessee, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"2021010504001459900_CIT0001","volume-title":"Renflexis [package insert]","year":"2017"},{"issue":"5","key":"2021010504001459900_CIT0002","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jaip.2017.04.044","article-title":"First-dose anaphylaxis to infliximab: a case of mammalian meat allergy","volume":"5","author":"Chitnavis","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2021010504001459900_CIT0003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumour necrosis factor and Crohn\u2019s disease","volume":"40","author":"Van Deventer","year":"1997","journal-title":"Gut"},{"issue":"9","key":"2021010504001459900_CIT0004","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2021010504001459900_CIT0005","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.gtc.2006.09.006","article-title":"Infusion reactions and their management","volume":"35","author":"Mayer","year":"2006","journal-title":"Gastroenterol Clin North Am"},{"key":"2021010504001459900_CIT0006","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2021010504001459900_CIT0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"issue":"4","key":"2021010504001459900_CIT0008","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.dld.2018.12.002","article-title":"Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"51","author":"Fumery","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2021010504001459900_CIT0009","volume-title":"Remicade [package insert]","year":"2017"},{"key":"2021010504001459900_CIT0010","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1710-1492-7-S1-S9","article-title":"Urticaria and angioedema","volume":"7","author":"Kanani","year":"2011","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2021010504001459900_CIT0011","doi-asserted-by":"crossref","first-page":"26438","DOI":"10.1155\/2007\/26438","article-title":"Angioedema: clinical and etiological aspects","volume":"2007","author":"Kulthanan","year":"2007","journal-title":"Clin Dev Immunol"},{"issue":"S1","key":"2021010504001459900_CIT0012","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/01.MIB.0000480055.04193.f1","article-title":"Idiopathic angioedema associated with Crohn\u2019s disease: response to vedolizumab","volume":"22","author":"Mason","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"34","key":"2021010504001459900_CIT0013","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3748\/wjg.v18.i34.4787","article-title":"Angioedema associated with Crohn\u2019s disease: response to biologics","volume":"18","author":"Habal","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"8","key":"2021010504001459900_CIT0014","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2021010504001459900_CIT0015","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2021010504001459900_CIT0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antib8010021","article-title":"Immunogenicity of innovative and biosimilar monoclonal antibodies","volume":"8","author":"Doevendans","year":"2019","journal-title":"Antibodies"},{"issue":"1","key":"2021010504001459900_CIT0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apt.14997","article-title":"Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab","volume":"49","author":"Feagan","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2021010504001459900_CIT0018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"2021010504001459900_CIT0019","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.anai.2015.06.004","article-title":"Adverse reactions to infliximab and the outcome of desensitization","volume":"115","author":"Mourad","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"2021010504001459900_CIT0020","first-page":"3","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/2\/108\/35390477\/zxaa321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/2\/108\/35390477\/zxaa321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T14:36:49Z","timestamp":1609857409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/2\/108\/5919599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,8]]},"published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa321","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,15]]},"published":{"date-parts":[[2020,10,8]]}}}